A 42-year-old woman presents with a 2-week history of progressive right eye pain, diplopia (especially on lateral gaze), and mild proptosis. MRI shows a well-defined mass in the cavernous sinus with enhancement. There is no fever or systemic toxicity. What is the most appropriate next step in management?

Explanation

## Cavernous Sinus Mass: Suspected Idiopathic Inflammatory Disease (Tolosa-Hunt Syndrome) The clinical presentation of **subacute eye pain, diplopia on lateral gaze (CN VI palsy), and mild proptosis** in a middle-aged woman, with a **well-defined enhancing cavernous sinus mass** and **no fever or systemic toxicity**, is classic for **Tolosa-Hunt Syndrome (THS)** or IgG4-related orbital/cavernous sinus disease — both idiopathic inflammatory conditions. ## Key Diagnostic Features Supporting Idiopathic Inflammation | Feature | This Patient | |---------|-------------| | Age/sex | Middle-aged woman (typical) | | Pain | Periorbital/retro-orbital (hallmark of THS) | | Cranial nerve involvement | CN VI (lateral gaze diplopia) | | Proptosis | Mild (inflammatory edema) | | Imaging | Well-defined enhancing mass, no bony destruction | | Systemic toxicity | Absent | | Fever | Absent | ## Why High-Dose Corticosteroids First? **Key Point:** Per the **International Headache Society (IHS) criteria**, Tolosa-Hunt Syndrome is defined as painful ophthalmoplegia with granulomatous inflammation on MRI or biopsy, and **dramatic response to corticosteroids is both diagnostic and therapeutic**. High-dose steroids (prednisone 1 mg/kg/day or equivalent) are the **first-line management**, with repeat MRI in 4–6 weeks to confirm resolution. **High-Yield:** The "steroid test" serves a dual purpose: - **Therapeutic** — rapid symptom relief (often within 72 hours) in THS/IgG4 disease - **Diagnostic** — failure to respond prompts biopsy to exclude lymphoma, meningioma, or metastasis **Clinical Pearl (Harrison's Principles of Internal Medicine):** In the absence of red flags (bony destruction, systemic B symptoms, rapid progression, or failure to respond to steroids), empirical corticosteroids are appropriate and biopsy is reserved for steroid-refractory or atypical cases. This approach avoids the significant morbidity of cavernous sinus biopsy when a benign inflammatory etiology is strongly suspected. ## Why Not the Other Options? - **Option A (Empirical antibiotics):** No fever, no systemic toxicity, no risk factors for cavernous sinus thrombosis/abscess. Antibiotics are not indicated and delay appropriate treatment. - **Option C (Immediate biopsy before any treatment):** Biopsy of the cavernous sinus carries significant risk (CN injury, vascular injury). Guidelines recommend a **steroid trial first** in suspected THS; biopsy is reserved for steroid-refractory cases or when malignancy is strongly suspected. Proceeding directly to biopsy without a therapeutic trial is not the standard of care for this presentation. - **Option D (Immediate surgical decompression):** There is no evidence of compressive emergency (vision loss, severe proptosis, or herniation). Immediate surgery is not indicated and carries unnecessary morbidity. ## Management Algorithm ``` Cavernous sinus mass + painful ophthalmoplegia + no systemic toxicity ↓ High-dose corticosteroids (prednisone 1 mg/kg/day) ↓ Repeat MRI at 4–6 weeks ↓ Resolution → Confirm THS/IgG4, taper steroids No response → Biopsy to exclude lymphoma/malignancy ``` **Mnemonic:** **THS = Try High-dose Steroids** — dramatic response confirms idiopathic inflammation; failure mandates tissue diagnosis. *Reference: Harrison's Principles of Internal Medicine, 21st ed.; IHS Classification ICHD-3 (Tolosa-Hunt Syndrome criteria)*